{"prompt": "['Alliance A171601', 'KIT#1:', 'IFN-gamma,IL-1beta,IL-2,IL-4,IL-6,IL-8,IL-10,IL-12p70,IL-13, TNF-alpha', 'Level of detection:', 'IFN-y: 0.04 pg/mL', 'IL-2:0.22 pg/mL', 'IL-4: 0.14 pg/mL', 'IL-5:0.07 pg/mL', 'IL-6:0.61 pg/mL', 'KC/GRO: 0.24 pg/mL', 'IL-10: 0.95 pg/mL', 'IL-12p70:9.95pp/mL', 'TNF-a: 0.13 pg/mL', 'KIT#2:', 'Eotaxin, MIP-1beta, Eotaxin-3, TARC, IP-10, MIP-1alpha, IL-8, MCP-1, MDC,', 'MCP-4', 'Level of detection:', 'Eotaxin: 3.26 pg/mL', 'MIP-1B: 0.37 pg/mL', 'Eotaxin-3: 1.77 pg/mL', 'TARC: 0.22 pg/mL', 'IP-10: 0.37 pg/mL', 'MIP-1a: 3.02 pg/mL', 'IL-8(HA): 95.6 pg/mL', 'MCP-1: 0.09 pg/mL', 'MDC: 1.22 pg/mL', 'MCP-4: 1.69 pg/mL', 'KIT#3:', 'CRP, ICAM-1, SAA, VCAM-1', 'Level of detection:', 'SAA: 10.9 pg/mL', 'CRP: 1.33 pg/mL', 'VCAM-1: 6.00 pg/mL', 'ICAM-1: 1.03 pg/mL', 'KIT#4:', 'TNFR1 and TNFR2', \"TNF-R1: Intra-assay C.V.'s are 6.9%, 3.1%, and 4.2% at 61.01, 4426.3, and\", '3841.2 pg/mL respectively.', \"TNF-R2: Intra-assay C.V.'s are 2.6%, 3.6%, and 3.4% at 126.6, 7158.6, and\", '6120.5 pg/mLrespectively.', '66', 'NCI Version Date: 5/29/2020', 'Update 5']['Alliance A171601', 'KIT#5: D-dimer', 'Level of detection:', '110 - 2,000 ng/mL', 'The Immunochemical Core Laboratory at Mayo Clinic. The ICL is certified by', 'both the College of American Pathologists (CAP# 1808201, AU ID#1183832)', 'and the Department of Health and Human Services (CLIA ID# 24D0861265).', 'Regulatory requirements include thorough test validation, documentation,', 'standardized test procedures and review of quality control markers.', '14.1.4 Analyses', 'Baseline chronic inflammatory mediator levels will be summarized and presented', 'descriptively for all patients. The association between baseline chronic inflammatory', 'mediator levels and the rate of adverse events and treatment modifications will be assessed', 'graphically. Logistic regression models will also be utilized in an exploratory fashion to', 'assess these associations. To examine the association between baseline chronic', 'inflammatory mediator levels and the baseline geriatric assessment scores, we will use', \"graphical means and Spearman's correlation coefficient. Exploratory linear regression\", 'models will also be utilized for this aim. The association between baseline chronic', 'inflammatory mediator levels and the change in the geriatric assessment through time will', 'be analyzed graphically and with exploratory repeated measures models.', '14.2 Pharmacogenomics: (Alliance A171601-ST2): Genetic determinants of Palbociclib', 'Efficacy and toxicity in the elderly', 'Alliance A171601-ST2 will evaluate genetic determinants of palbociclib efficacy and toxicity', 'in elderly patients with estrogen receptor positive, HER2 negative metastatic breast cancer', '14.2.1 Background', 'Multiple endocrine therapy options exist for treatment and prevention of breast cancer in', 'post-menopausal women with estrogen receptor positive breast (HR positive) cancers.98', '100 Aromatase inhibitors (AI) such as letrozole, anastrozole and exemestane which function', 'by inhibiting the aromatase enzyme (CYP19), have improved the recurrence rates of breast', 'cancer after 5 years of tamoxifen treatment compared to placebo. 100 However, side effects', 'notably musculoskeletal symptoms, from AI therapy have led to intolerance and subsequent', 'discontinuation of treatment. 101-102 Data accumulated over the period now suggests that the', 'benefits associated with prolonged endocrine therapy should be balanced with treatment', 'tolerability and fracture risks103', 'Post-menopausal women with metastatic HR positive breast cancers are treated with', 'fulvestrant which acts differently from the AIs by targeting the estrogen receptor. As an', 'antagonist, fulvestrant binds to estrogen receptors competitively on tumors and other tissue', 'targets, producing anuc lear complex that causes a dose-related down-regulation of estrogen', 'receptors and inhibits tumor growth. 104 For advanced metastatic breast cancers exhibiting', 'both HR-positive and human epidermal growth factor receptor 2 (HER2)-negativ', 'characteristics, improved progression free survival has been associated with treatment', 'options that include an AI or fulvestrant together with a cyclin-dependent kinase (CDK) 4/6', 'inhibitor such as palbocic lib. 105-107', 'Palbociclib has been shown to specifically inhibit CDK 4/6 by blocking the progression of', 'cells from G1 into S phase of the cell cycle and resulting in reduced cellular proliferation of', 'ER-positive breast cancer cell lines 108,109 Reports indicate that palbocicl lib enhances the', '67', 'NCI Version Date: 5/29/2020', 'Update 5']\n\n###\n\n", "completion": "END"}